Iteos Historical Income Statement

ITOS Stock

USD 8.55 0.01 0.12%

Historical analysis of Iteos Therapeutics income statement accounts such as Interest Income of 32.4 M or Depreciation And Amortization of 1.3 M can show how well Iteos Therapeutics performed in making a profits. Evaluating Iteos Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Iteos Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Iteos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iteos Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

About Iteos Income Statement Analysis

Iteos Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Iteos Therapeutics shareholders. The income statement also shows Iteos investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Iteos Therapeutics Income Statement Chart

At this time, Iteos Therapeutics' Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 32.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 29.9 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Iteos Therapeutics. It is also known as Iteos Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Iteos Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Iteos Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.At this time, Iteos Therapeutics' Net Interest Income is comparatively stable compared to the past year. Interest Income is likely to gain to about 32.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 29.9 M in 2024.

	2022	2023	2024 (projected)
Depreciation And Amortization	813K	898K	1.3M
Interest Income	11.4M	30.9M	32.4M

Depreciation And Amortization Interest Income

Iteos Therapeutics income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Non Operating Income Net Other
Tax Provision		0.12	0.12	-0.07	0.37	0.7	0.63	0.79	0.86	0.8	0.61	0.8	0.63	0.48	0.86	0.3	0.79	1.0	0.97	0.38	0.38
Net Interest Income	0.12		1.0	0.02	0.95	0.71	0.77	-0.47	-0.23	-0.46	0.78	-0.46	0.77	0.85	-0.34	0.97	-0.43	0.12	0.04	0.87	0.95
Interest Income	0.12	1.0		0.02	0.95	0.71	0.77	-0.47	-0.23	-0.46	0.78	-0.46	0.77	0.85	-0.34	0.97	-0.43	0.12	0.04	0.87	0.95
Depreciation And Amortization	-0.07	0.02	0.02		0.0	0.0	-0.03	-0.09	-0.09	-0.1	-0.04	-0.08	-0.03	0.18	-0.09	0.09	-0.09	-0.07	-0.08	0.01	0.0
Interest Expense	0.37	0.95	0.95	0.0		0.81	0.87	-0.27	-0.06	-0.25	0.88	-0.25	0.87	0.92	-0.14	0.96	-0.24	0.37	0.25	0.93	1.0
Selling General Administrative	0.7	0.71	0.71	0.0	0.81		0.98	0.21	0.43	0.22	0.97	0.22	0.98	0.91	0.34	0.84	0.25	0.7	0.66	0.8	0.81
Other Operating Expenses	0.63	0.77	0.77	-0.03	0.87	0.98		0.08	0.29	0.1	1.0	0.1	1.0	0.96	0.21	0.86	0.12	0.63	0.55	0.89	0.87
Operating Income	0.79	-0.47	-0.47	-0.09	-0.27	0.21	0.08		0.96	1.0	0.06	1.0	0.08	-0.11	0.99	-0.29	1.0	0.79	0.86	-0.22	-0.26
Net Income From Continuing Ops	0.86	-0.23	-0.23	-0.09	-0.06	0.43	0.29	0.96		0.96	0.27	0.96	0.29	0.1	0.99	-0.04	0.98	0.86	0.95	-0.02	-0.05
Ebit	0.8	-0.46	-0.46	-0.1	-0.25	0.22	0.1	1.0	0.96		0.07	1.0	0.1	-0.1	0.99	-0.28	1.0	0.8	0.87	-0.21	-0.24
Research Development	0.61	0.78	0.78	-0.04	0.88	0.97	1.0	0.06	0.27	0.07		0.07	1.0	0.96	0.19	0.86	0.09	0.62	0.53	0.9	0.88
Ebitda	0.8	-0.46	-0.46	-0.08	-0.25	0.22	0.1	1.0	0.96	1.0	0.07		0.1	-0.09	0.99	-0.28	1.0	0.8	0.87	-0.21	-0.24
Total Operating Expenses	0.63	0.77	0.77	-0.03	0.87	0.98	1.0	0.08	0.29	0.1	1.0	0.1		0.96	0.21	0.86	0.12	0.63	0.55	0.89	0.87
Reconciled Depreciation	0.48	0.85	0.85	0.18	0.92	0.91	0.96	-0.11	0.1	-0.1	0.96	-0.09	0.96		0.02	0.91	-0.08	0.48	0.38	0.94	0.92
Income Before Tax	0.86	-0.34	-0.34	-0.09	-0.14	0.34	0.21	0.99	0.99	0.99	0.19	0.99	0.21	0.02		-0.15	0.99	0.86	0.92	-0.1	-0.13
Total Other Income Expense Net	0.3	0.97	0.97	0.09	0.96	0.84	0.86	-0.29	-0.04	-0.28	0.86	-0.28	0.86	0.91	-0.15		-0.24	0.3	0.23	0.86	0.96
Net Income	0.79	-0.43	-0.43	-0.09	-0.24	0.25	0.12	1.0	0.98	1.0	0.09	1.0	0.12	-0.08	0.99	-0.24		0.79	0.88	-0.2	-0.23
Income Tax Expense	1.0	0.12	0.12	-0.07	0.37	0.7	0.63	0.79	0.86	0.8	0.62	0.8	0.63	0.48	0.86	0.3	0.79		0.97	0.38	0.38
Gross Profit	0.97	0.04	0.04	-0.08	0.25	0.66	0.55	0.86	0.95	0.87	0.53	0.87	0.55	0.38	0.92	0.23	0.88	0.97		0.25	0.25
Cost Of Revenue	0.38	0.87	0.87	0.01	0.93	0.8	0.89	-0.22	-0.02	-0.21	0.9	-0.21	0.89	0.94	-0.1	0.86	-0.2	0.38	0.25		0.94
Non Operating Income Net Other	0.38	0.95	0.95	0.0	1.0	0.81	0.87	-0.26	-0.05	-0.24	0.88	-0.24	0.87	0.92	-0.13	0.96	-0.23	0.38	0.25	0.94

Click cells to compare fundamentals

Iteos Therapeutics Account Relationship Matchups

Iteos Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	119K	(57K)	41.9M	52.1M	3.5M	3.4M
Depreciation And Amortization	6.3M	535K	615K	813K	898K	1.3M
Interest Expense	0.0	1.2M	1.4M	19.1M	22.0M	23.1M
Selling General Administrative	8.8M	15.3M	40.5M	43.9M	50.4M	29.9M
Other Operating Expenses	23.3M	39.3M	89.7M	138.0M	163.7M	86.5M
Operating Income	(28.0M)	(45.2M)	244.9M	126.3M	(151.1M)	(143.5M)
Net Income From Continuing Ops	(22.5M)	(38.0M)	214.5M	96.7M	(61.6M)	(58.6M)
Ebit	(28.0M)	(38.4M)	256.5M	147.6M	(152.0M)	(144.4M)
Research Development	19.2M	29.9M	59.4M	97.4M	113.3M	61.7M
Ebitda	(21.7M)	(37.8M)	257.1M	148.4M	(151.1M)	(143.5M)
Total Operating Expenses	23.3M	39.3M	89.7M	138.0M	163.7M	86.5M
Reconciled Depreciation	611K	535K	603K	803K	894K	724.4K
Income Before Tax	(22.3M)	(38.1M)	256.5M	148.7M	(109.0M)	(103.6M)
Total Other Income Expense Net	5.7M	7.2M	11.6M	22.4M	42.1M	44.2M
Net Income Applicable To Common Shares	(26.5M)	(43.4M)	214.5M	96.7M	111.1M	116.7M
Net Income	(22.5M)	(38.0M)	214.5M	96.7M	(112.6M)	(107.0M)
Income Tax Expense	119K	(57K)	41.9M	52.1M	3.6M	3.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iteos Historical Income Statement

About Iteos Income Statement Analysis

Iteos Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Iteos Therapeutics income statement Correlations

Iteos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iteos Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Iteos Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Tax Expense	+ 1.0	Tax Provision
Interest Income	+ 1.0	Net Interest Income
Non Operating Income Net Other	+ 1.0	Interest Expense
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income

Operating Income	- 0.47	Interest Income
Operating Income	- 0.47	Net Interest Income
Ebitda	- 0.46	Interest Income
Ebit	- 0.46	Interest Income
Ebitda	- 0.46	Net Interest Income
Ebit	- 0.46	Net Interest Income